CoChat
Sign Up
Cited by 94

microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus

Jimenez-Mateos, Eva M., Arribas-Blazquez, Marina, Sanz-Rodriguez, Amaya, Concannon, Caoimhin, Olivos-Ore, Luis A., Reschke, Cristina R., Mooney, Claire M., Mooney, Catherine +14 more·2015·Scientific Reports
DOI 10.1038/srep17486PMC PMC4668358
Open this paper in CoChat — free account

Abstract

The ATP-gated ionotropic P2X7 receptor (P2X7R) modulates glial activation, cytokine production and neurotransmitter release following brain injury. Levels of the P2X7R are increased in experimental and human epilepsy but the mechanisms controlling P2X7R expression remain poorly understood. Here we investigated P2X7R responses after focal-onset status epilepticus in mice, comparing changes in the damaged, ipsilateral hippocampus to the spared, contralateral hippocampus. P2X7R-gated inward currents were suppressed in the contralateral hippocampus and P2rx7 mRNA was selectively uploaded into the RNA-induced silencing complex (RISC), suggesting microRNA targeting. Analysis of RISC-loaded microRNAs using a high-throughput platform, as well as functional assays, suggested the P2X7R is a target of microRNA-22. Inhibition of microRNA-22 increased P2X7R expression and cytokine levels in the contralateral hippocampus after status epilepticus and resulted in more frequent spontaneous seizures in mice. The major pro-inflammatory and hyperexcitability effects of microRNA-22 silencing were prevented in P2rx7−/− mice or by treatment with a specific P2X7R antagonist. Finally, in vivo injection of microRNA-22 mimics transiently suppressed spontaneous seizures in mice. The present study supports a role for post-transcriptional regulation of the P2X7R and suggests therapeutic targeting of microRNA-22 may prevent inflammation and development of a secondary epileptogenic focus in the brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep17486

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 70

  1. Chang B. S. & Lowenstein D. H. Epilepsy. New Engl J Med 349, 1257– 1266 (2003). 14507951
  2. Vezzani A., French J., Bartfai T. & Baram T. Z. The role of inflammation in epilepsy. Nat Rev Neurol 7, 31– 40 (2011). 21135885 PMC3378051
  3. Marchi N., Granata T. & Janigro D. Inflammatory pathways of seizure disorders. Trend Neurosci 37, 55– 65 (2014). 24355813 PMC3977596
  4. Pernot F. et al. Inflammatory changes during epileptogenesis and spontaneous seizures in a mouse model of mesiotemporal lobe epilepsy. Epilepsia 52, 2315– 2325 (2011). 21955106
  5. Gershen L. D. et al. Neuroinflammation in temporal lobe epilepsy measured using positron emission tomographic imaging of translocator protein. JAMA neurology 72, 882– 888 (2015). 26052981 PMC5234042
  6. Khalilov I., Holmes G. L. & Ben-Ari Y. In vitro formation of a secondary epileptogenic mirror focus by interhippocampal propagation of seizures. Nat Neurosci 6, 1079– 1085 (2003). 14502289
  7. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Disc 7, 575– 590 (2008). 18591979
  8. North R. A. Molecular physiology of P2X receptors. Physiol Rev 82, 1013– 1067 (2002). 12270951
  9. Henshall D. C., Diaz-Hernandez M., Miras-Portugal M. T. & Engel T. P2X receptors as targets for the treatment of status epilepticus. Front Cell Neurosci 7, 237 (2013). 24324404 PMC3840793
  10. Rappold P. M., Lynd-Balta E. & Joseph S. A. P2X7 receptor immunoreactive profile confined to resting and activated microglia in the epileptic brain. Brain Res 1089, 171– 178 (2006). 16635480
  11. Mingam R. et al. In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1 beta in the murine brain. Brain Behav Immun 22, 234– 244 (2008). 17905568 PMC2908086
  12. Monif M., Reid C. A., Powell K. L., Smart M. L. & Williams D. A. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci 29, 3781– 3791 (2009). 19321774 PMC6665035
  13. Armstrong J. N., Brust T. B., Lewis R. G. & MacVicar B. A. Activation of presynaptic P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. J Neurosci 22, 5938– 5945 (2002). 12122056 PMC6757920
  14. Sperlagh B. et al. Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J Neurochem 81, 1196– 1211 (2002). 12068068
  15. Dona F. et al. Alteration of purinergic P2X4 and P2X7 receptor expression in rats with temporal-lobe epilepsy induced by pilocarpine. Epilepsy Res 83, 157– 167 (2009). 19084381
  16. Jimenez-Pacheco A. et al. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia 54, 1551– 1561 (2013). 23808395
  17. Engel T. et al. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J 26, 1616– 1628 (2012). 22198387
  18. Mesuret G. et al. P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage. CNS Neurosci Thera 20, 556– 564 (2014). PMC6493144 24750893
  19. Soni N., Koushal P., Reddy B. V., Deshmukh R. & Kumar P. Effect of GLT-1 modulator and P2X7 antagonists alone and in combination in the kindling model of epilepsy in rats. Epilepsy Behav 48, 4– 14 (2015). 26037843
  20. Zhou L., Qi X., Potashkin J. A., Abdul-Karim F. W. & Gorodeski G. I. MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3′-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem 283, 28274– 28286 (2008). 18682393 PMC2568908
  21. Huang S. et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One 8, e80707 (2013). 24312495 PMC3846619
  22. Bartel D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281– 297 (2004). 14744438
  23. Fabian M. R., Sonenberg N. & Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79, 351– 379 (2010). 20533884
  24. Czech B. & Hannon G. J. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 12, 19– 31 (2011). 21116305 PMC3703915
  25. Henshall D. C. MicroRNA and epilepsy: profiling, functions and potential clinical applications. Curr Opin Neurol 27, 199– 205 (2014). 24553459 PMC4127484
  26. Jimenez-Mateos E. M. et al. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med 18, 1087– 1094 (2012). 22683779 PMC3438344
  27. Tan C. L. et al. MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science 342, 1254– 1258 (2013). 24311694 PMC3932786
  28. Letellier M. et al. miR-92a regulates expression of synaptic GluA1-containing AMPA receptors during homeostatic scaling. Nat Neurosci 17, 1040– 1042 (2014). 25017011
  29. Araki T., Simon R. P., Taki W., Lan J. Q. & Henshall D. C. Characterization of neuronal death induced by focally evoked limbic seizures in the C57BL/6 mouse. J Neurosci Res 69, 614– 621 (2002). 12210827
  30. Mouri G. et al. Unilateral hippocampal CA3-predominant damage and short latency epileptogenesis after intra-amygdala microinjection of kainic acid in mice. Brain Res. 1213, 140– 151 (2008). 18455706
  31. Paxinos G. & Franklin K. B. J. The mouse brain in stereotaxic coordinates, second edition, (Elsevier, San Diego, CA, 2001).
  32. Jimenez-Mateos E. M. et al. Antagomirs targeting microRNA-134 increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced status epilepticus. Brain Struc Func 220, 2387– 2399 (2015). 24874920
  33. Jimenez-Mateos E. M. et al. Hippocampal transcriptome after status epilepticus in mice rendered seizure damage-tolerant by epileptic preconditioning features suppressed calcium and neuronal excitability pathways. Neurobiol Dis 32, 442– 453 (2008). 18804535
  34. Junker A. et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132, 3342– 3352 (2009). 19952055
  35. Pradervand S. et al. Impact of normalization on miRNA microarray expression profiling. RNA 15, 493– 501 (2009). 19176604 PMC2657010
  36. Huber W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods 12, 115– 121 (2015). 25633503 PMC4509590
  37. Kozomara A. & Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acid Res 42, D68– 73 (2014). 24275495 PMC3965103
  38. Engel T. et al. CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. Brain 136, 577– 592 (2013). 23361066
  39. Allan S. M., Tyrrell P. J. & Rothwell N. J. Interleukin-1 and neuronal injury. Nat Rev Immunol 5, 629– 640 (2005). 16034365
  40. Flores O., Kennedy E. M., Skalsky R. L. & Cullen B. R. Differential RISC association of endogenous human microRNAs predicts their inhibitory potential. Nucleic Acid Res 42, 4629– 4639 (2014). 24464996 PMC3985621
  41. Bhattacharya A. et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol 170, 624– 640 (2013). 23889535 PMC3792000
  42. Bouchie A. First microRNA mimic enters clinic. Nat Biotech 31, 577 (2013). 23839128
  43. Henshall D. C. MicroRNAs in the pathophysiology and treatment of status epilepticus. Front Mol Neurosci 6, 1– 11 (2013). PMC3824358 24282394
  44. Kan A. A. et al. Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. Cell Mol Life Sci 69, 3127– 3145 (2012). 22535415 PMC3428527
  45. McKiernan R. C. et al. Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLoS One 7, e35921 (2012). 22615744 PMC3352899
  46. Zucchini S. et al. Identification of miRNAs differentially expressed in human epilepsy with or without granule cell pathology. PLoS One 9, e105521 (2014). 25148080 PMC4141756
  47. Miller-Delaney S. F. et al. Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy. Brain 138, 616– 631 (2015). 25552301 PMC4408428
  48. Hu K. et al. Expression profile of microRNAs in rat hippocampus following lithium-pilocarpine-induced status epilepticus. Neurosci Lett 488, 252– 257 (2011). 21094214
  49. Risbud R. M. & Porter B. E. Changes in microRNA expression in the whole hippocampus and hippocampal synaptoneurosome fraction following pilocarpine induced status epilepticus. PLoS One 8, e53464 (2013). 23308228 PMC3538591
  50. Xiong J., Du Q. & Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 29, 4980– 4988 (2010). 20562918
  51. Jovicic A., Zaldivar Jolissaint J. F., Moser R., Silva Santos Mde F. & Luthi-Carter R. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington’s disease-related mechanisms. PLoS One 8, e54222 (2013). 23349832 PMC3547907
  52. Yu H. et al. Neuroprotective effects of viral overexpression of microRNA-22 in rat and cell models of cerebral ischemia-reperfusion injury. J Cell Biochem 116, 233– 241 (2015). 25186498
  53. Vale F. L., Pollock G. & Benbadis S. R. Failed epilepsy surgery for mesial temporal lobe sclerosis: a review of the pathophysiology. Neurosurg Focus 32, E9 (2012). 22380863
  54. Hegde M. & Lowenstein D. H. The search for circulating epilepsy biomarkers. Biomarkers Med 8, 413– 427 (2014). 24712433
  55. Wilczynska A. & Bushell M. The complexity of miRNA-mediated repression. Cell Death Differ 22, 22– 33 (2015). 25190144 PMC4262769
  56. Lee K. et al. An activity-regulated microRNA, miR-188, controls dendritic plasticity and synaptic transmission by downregulating neuropilin-2. J Neurosci 32, 5678– 5687 (2012). 22514329 PMC5010781
  57. Berenguer J. et al. MicroRNA 22 regulates cell cycle length in cerebellar granular neuron precursors. Mol Cell Biol 33, 2706– 2717 (2013). 23671190 PMC3700129
  58. Gavala M. L., Hill L. M., Lenertz L. Y., Karta M. R. & Bertics P. J. Activation of the transcription factor FosB/activating protein-1 (AP-1) is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells. J Biol Chem 285, 34288– 34298 (2010). 20813842 PMC2962527
  59. Watanabe Y. et al. Null mutation of c-fos impairs structural and functional plasticities in the kindling model of epilepsy. J Neurosci 16, 3827– 3836 (1996). 8656277 PMC6578612
  60. Ferrari D., Wesselborg S., Bauer M. K. & Schulze-Osthoff K. Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol 139, 1635– 1643 (1997). 9412459 PMC2132650
  61. Kim J. E. & Kang T. C. The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. J Clin Invest 121, 2037– 2047 (2011). 21505260 PMC3083785
  62. Boison D. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84, 249– 262 (2008). 18249058 PMC2278041
  63. Ortinski P. I. et al. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci 13, 584– 591 (2010). 20418874 PMC3225960
  64. Pascual O., Ben Achour S., Rostaing P., Triller A. & Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 109, E197– 205 (2012). 22167804 PMC3268269
  65. Brough D., Le Feuvre R. A., Iwakura Y. & Rothwell N. J. Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol Cell Neurosci 19, 272– 280 (2002). 11860279
  66. Salter M. W. & Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 158, 15– 24 (2014). 24995975
  67. Chandradoss S. D., Schirle N. T., Szczepaniak M., MacRae I. J. & Joo C. A dynamic search process underlies microRNA targeting. Cell 162, 96– 107 (2015). 26140593 PMC4768356
  68. Garcia-Huerta P. et al. The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system. J Biol Chem 287, 44628– 44644 (2012). 23139414 PMC3531778
  69. Ebert M. S. & Sharp P. A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515– 524 (2012). 22541426 PMC3351105
  70. Broderick J. A. & Zamore P. D. MicroRNA therapeutics. Gene Thera 18, 1104– 1110 (2011). PMC3237828 21525952

Cited by

Sorted by citations

Authors
Jimenez-Mateos, E. M., Arribas-Blazquez, M., Sanz-Rodriguez, A., Concannon, C., Olivos-Ore, L. A., Reschke, C. R., Mooney, C. M., Mooney, C., Lugara, E., Morgan, J., Langa, E., Jimenez-Pacheco, A., Silva, L. F. A., Mesuret, G., Boison, D., Miras-Portugal, M. T., Letavic, M., Artalejo, A. R., Bhattacharya, A., Diaz-Hernandez, M., Henshall, D. C., & Engel, T.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2015-12-03
Volume
5
Issue
1
ISSN
2045-2322
DOI
10.1038/srep17486
PMC
PMC4668358
Cited by
94
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review